FDA
-
-
-
-
-
-
-
Arcellx presents anito-cel research at 2026 Tandem Meetings
-
-
-
-
-
-
-
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
-
-
-
-
-
-
-
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-
-
-
-
-
-
-
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
-
-
-
-
-
-
-
Arcellx Provides First Quarter Financial Results
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

